GBA Presents: THE BARE ESSENTIALS

Hopefully I can get out of ASO today on a high note-- Although I fear it will trade willdown-

Academy Sports sees FY22 EPS $6.70-$7.25, consensus $6.14 08:10 ASO Sees FY22 revenue… >> Academy Sports reports Q4 pro forma EPS $1.61, consensus $1.37 08:10 ASO Reports Q4 revenue…
 
Lovesac reports Q4 EPS $2.03, consensus 54c 07:08 LOVE Reports Q4 revenue $196.198M, consensus $174.33M. Shawn Nelson, Chief Executive Officer, stated, "Lovesac's continued strong financial performance in the face of a myriad of macro and industry shifts affirms the power of our unique business model and products. Importantly, the key distinguishing attributes of this model, which include operational flexibility, highly-engaged customers, innovation and a proven omni-channel approach, will only grow stronger over time as our progress along the product adoption curve steepens and word of mouth continues to gain strength. This curve will benefit further from deep stock positions that allow us to deliver and execute for our customers in a more timely manner, leading to further share gains and solidified customer loyalty. We also continue to identify and drive operational initiatives that will lead to even greater improvements in our bottom-line results as we continue to scale the business." Nelson continued, "We enter fiscal 2023 with the people, strategy and platform primed to build on our success and deliver long-term, sustainable and profitable growth. We'll drive this growth by remaining focused on key drivers: smart investments in product extensions and technology, creative deployment of our omni-channel sales model, supply chain and operating efficiencies. I am immensely proud of our resilient and passionate team and we are eager and enthusiastic for a successful fiscal 2023."
 
Dave & Buster trade set up____

Dave & Buster's says Q1 business has strengthened vs. 2019 so far 17:03 PLAY The Company's states that its "business has strengthened through the first eight weeks of the first quarter, during which comparable store sales increased 5.4% compared with the same period in 2019. Walk-in comparable store sales increased 9.1% while Special Event comparable store sales declined 42.0% for the eight-week period compared with 2019."

Dave & Buster's reports Q4 EPS 52c, consensus 60c » 17:02 PLAY Reports Q4 revenue…
 
Wolfspeed initiated with an Outperform at SMBC Nikko 16:44 WOLF SMBC Nikko analyst Srini Pajjuri initiated coverage of Wolfspeed with an Outperform rating and $140 price target. The company is the "undisputed leader" in the silicon carbide market, which is characterized by complex manufacturing and high barriers to entry, Pajjuri tells investors in a research note. The analyst expects SiC demand to outpace supply for the next several years driven by the electric vehicle "megatrend" and broader shift toward energy efficiency. Wolfspeed's valuation is not inexpensive but is justified given its "strong secular growth and significant technology/manufacturing moat," Pajjuri tells investors in a research note.
 
Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M 16:03 DNA Ginkgo expects to add 60 new Cell Programs to the Foundry platform in 2022. Show Related Items >>

-STOCK OF THE DAY- EVLV

Description

Evolv Technologies Holdings, Inc. provides AI-based touchless security screening systems. The company offers an array of AI- based touchless screening technologies for weapons detection, identity verification, and health-related threats. Its products include Evolv Express, a touchless security screening system designed to detect firearms, improvised explosive devices, and tactical knives as visitors walk through at a normal pace, individually or in groups; Evolv Insights that provides detailed analytics about visitor flows and Evolv Express detection performance; Evolv Thermal Imaging Package; and Evolv Edge to detect non-metallic explosive devices, metallic explosive devices, firearms, and tactical knives without requiring visitors to divest or empty their pockets. The company is based in Waltham, Massachusetts.


(EVLV)

2.6500+0.2800(+11.81%)
At close: March 28 04:00PM EDT

Volume Yest-->1,526,471
Avg. Volume--> 870,075
 
  • Director of Evolv Technologies (EVLV) Kevin Charlton purchased 100,000 shares of company stock at $1.82 per share for a total transaction amount of $182,420


  • Director of Revolution Medicines (RVMD) Thilo Schroeder purchased 232,364 shares of company stock at $23.63 per share for a total transaction amount of $5,489,623

  • Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

    a80dee2d4a8acb423d8095dbdf6a84d4

    Revolution Medicines, Inc.

    Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging Targets” Sessions and Pediatric Cancer Working Group Town Hall Meeting

    REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.

  • Revolution Medicines(RVMD)

    The first stock we’ll look at, Revolution Medicines, is a precision oncology company working on two innovative research tracks designed to specifically inhibit frontier targets in RAS-addicted cancers. Revolution’s pipeline includes three drug candidates on the RAS companion inhibitor track, including two that have reached the stage of human clinical trials, and five more drug candidates in the RAS(ON) inhibitor track. All of the latter are in preclinical stages, with four of them in the process of preparing and submitting Investigational New Drug (IND) applications.

    On the RAS(ON) track, four of Revolution’s drug candidates are approaching the end of preclinical studies. RMC-6236, -6291, -9805, and -8839 are tri-complex inhibitors which Revolution Medicines has developed through its proprietary RAS(ON) platform. These drugs target ‘diverse oncogenic RAS variants,’ using a wide range of differentiated chemical and pharmacological profiles. The first two on track for IND completion in 1H22, while the second two are expected to complete their IND submissions in 2023.

    Turning to the clinical trials, we find that RMC-4630 is Revolution’s most advanced drug candidate so far. This drug is an SHP2 inhibitor, and is the subject of a global Phase 2 study, in combination with sotorasib, as a potential treatment for advanced non-small cell lung cancer. The company expects to complete enrollment in this study during 2H22, and to begin releasing data on clinical benefits before the end of the year. Additional data is expected during 2023. Revolution is conducting this study in partnership with Sanofi, and in 4Q21 the company received $9.5 million from Sanofi per the terms of their collaboration agreement.

    Revolution has one other clinical trial in progress, a Phase 1/1b study of RMC-5552. This drug, described as a ‘potent, selective bi-steric inhibitor of mTORC1,’ is in the dose escalation stage of the study, and the company recently released preliminary data showing positive clinical activity. The company plans on releasing additional data from this study of RMC-5552 as a single agent during 2023.

    Looking at the insider trades, we find that one Board member, Director Thilo Schroeder, has been making numerous large-sum purchases of RVMD stock. His most recent purchase, made on March 24 for $5.489 million, totaled 232,364 shares. His largest purchase, from March 4, was for 1.088 million shares and cost him $28.62 million. Overall, Schroeder has spent over $43 million on Revolution’s stock this month.

    Schroeder is not the only bull on this clinical-stage biopharma. Leerink analyst Jonathan Chang also takes a strongly positive stance here, writing: “We continue to have a positive long-term view on the stock based on RVMD's experienced management team, promising preclinical data for the innovative RAS(ON) platform, and large addressable population of RAS-dependent cancers. While the RAS pathway drug development landscape is highly competitive, we believe RVMD has a differentiated approach and the scientific ability to solve these challenging targets.”

    These upbeat comments back up Chang’s Outperform (i.e. Buy) rating on RVMD, and his $31 price target suggests the stock has a one-year upside of ~26%.



 
You must log in or register to reply here.
Back
Top